Mesoblast Limited

(NASDAQ:MESO)

Latest On Mesoblast Limited (MESO):

Date/Time Type Description Signal Details
2023-05-26 06:19 ESTNewsMesoblast Limited (MESO) Q3 2023 Earnings Call TranscriptN/A
2023-05-26 06:19 ESTNewsMesoblast GAAP EPS of -$0.025 beats by $0.13, revenue of $1.94M misses by $0.18MN/A
2023-05-04 20:51 ESTNewsMesoblast Has A Strong Upside PotentialN/A
2023-03-08 20:50 ESTNewsMesoblast stock surges ~10% on getting FDA review of graft versus host disease therapyN/A
2023-03-02 11:37 ESTNewsMesoblast Limited. (MESO) Q2 2023 Earnings Call TranscriptN/A
2023-02-28 14:47 ESTNewsMesoblast Limited 2023 Q2 - Results - Earnings Call PresentationN/A
2022-12-23 19:10 ESTNewsMesoblast and Oaktree extend availability of undrawn facilityN/A
2022-12-06 13:18 ESTNewsMesoblast stock falls 10% as Jefferies cuts rating to HoldN/A
2022-11-24 00:38 ESTNewsMesoblast Limited (MESO) Q1 2023 Earnings Call TranscriptN/A
2022-11-23 07:29 ESTNewsMesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82MN/A
2022-10-31 12:34 ESTNewsMesoblast reports operational and financial highlights for Q3N/A
2022-08-31 07:31 ESTNewsMesoblast Limited 2022 Q4 - Results - Earnings Call PresentationN/A
2022-08-31 07:31 ESTNewsMesoblast Limited (MESO) Q4 2022 Earnings Call TranscriptN/A
2022-08-31 07:31 ESTNewsMesoblast GAAP EPS of -$0.14, revenue of $10.21MN/A
2022-06-01 09:26 ESTNewsMesoblast GAAP EPS of -$0.03, revenue of $2MN/A
2022-02-02 13:18 ESTNewsNew medical chief at MesoblastN/A
2022-01-12 16:28 ESTNewsMesoblast’s rexlemestrocel-L results in durable pain reduction in degenerative disc diseaseN/A
2021-12-31 16:22 ESTNewsMesoblast to provide new data to FDA to support remestemcel-L BLA resubmissionN/A
2021-12-16 20:12 ESTNewsFDA’s OTAT in agreement pain reduction as primary endpoint in Mesoblast's Phase 3 programN/A
2021-12-14 07:58 ESTNewsMesoblast falls 8% after Novartis terminates deal prior to closingN/A
2021-12-06 08:59 ESTNewsMesoblast's rexlemestrocel-L shows treatment benefit in cardiovascular events in heart patientsN/A
2021-11-24 11:49 ESTNewsMesoblast EPS beats by $0.10, beats on revenueN/A
2021-11-22 16:32 ESTNewsMesoblast and Oaktree Capital refinance senior debt facilityN/A
2021-11-15 18:27 ESTNewsMesoblast's rexlemestrocel-l shows reduction in cardiovascular mortality, heart attacks and strokesN/A
2021-08-31 00:59 ESTNewsMesoblast EPS beats by $0.38N/A
2021-07-22 15:51 ESTNewsMesoblast reports FQ3 resultsN/A
2021-07-22 15:48 ESTNewsMesoblast provides update on rexlemestrocel-L in development for low back painN/A
2021-07-22 15:47 ESTNewsMesoblast reports respiratory function results of COVID-19 ARDS trialN/A
2021-07-22 15:47 ESTNewsMesoblast presents data showing mortality reduction of COVID-19 therapyN/A
2021-05-01 01:30 ESTNewsMESO, MOTS and SALM among premarket gainersN/A
2021-04-30 03:28 ESTNewsMesoblast's remestemcel-L reduces mortality by 46% in patients under age 65 with COVID-19 ARDSN/A
2021-04-08 03:05 ESTNewsMaxim upgrades Mesoblast to buy, sets $18 price targetN/A
2021-03-17 15:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.5 to $13.7.Neutral
2021-03-16 23:50 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.5.Neutral
2021-03-03 00:44 ESTNewsMesoblast announces a private placement of $110 millionN/A
2021-03-01 01:44 ESTEarnings EstimateAn EPS average of $0.03 is estimated for the quarter ending on March 31, 2021.Buy
2021-02-28 05:42 ESTFinancialsCompany financials have been released.Neutral
2021-02-17 14:54 ESTNewsMesoblast gains as remestemcel-l shows positive action in MIS-C post COVID-19N/A
2021-02-15 13:38 ESTAnalyst RatingThe Analyst Target Price has increased from $14.29 to $14.96.Buy
2021-02-12 12:18 ESTNewsMesoblast announces data from Phase 3 study in chronic back painN/A
2021-01-29 11:38 ESTNewsMesoblast issues FQ2 operational and financial updateN/A
2021-01-27 14:09 ESTAnalyst RatingThe Analyst Target Price has decreased from $14.96 to $14.29.Neutral
2021-01-19 22:20 ESTNewsMesoblast's Time May Be UpN/A
2021-01-11 12:34 ESTNewsMesoblast's rexlemestrocel-l reduces heart attacks, strokesN/A
2020-12-25 10:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.45 to $14.96.Neutral
2020-12-24 16:56 ESTNewsMesoblast: The Future Looks BleakN/A
2020-12-24 02:40 ESTAnalyst RatingThe Analyst Target Price has increased from $14.96 to $16.45.Buy
2020-12-23 18:45 ESTAnalyst RatingThe Analyst Target Price has decreased from $15.39 to $14.96.Neutral
2020-12-20 22:34 ESTAnalyst RatingThe Analyst Target Price has decreased from $16.82 to $15.39.Neutral
2020-12-18 05:21 ESTNewsMesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19N/A

About Mesoblast Limited (MESO):

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.

MESO Quotes by TradingView

See Advanced Chart

General

  • Name Mesoblast Limited
  • Symbol MESO
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 102
  • Fiscal Year EndJune
  • IPO Date2015-11-13
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.mesoblast.com
View More

Valuation

  • Forward PE 454.55
  • Price/Sales (Trailing 12 Mt.) 62.46
  • Price/Book (Most Recent Quarter) 2.28
  • Enterprise Value Revenue 70.47
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.29
  • Next Year EPS Estimate $0.17
  • Operating Margin -682%
  • Return on Assets -10%
  • Return on Equity -19%
  • Revenue 16.45 million
  • Earnings Per Share -$0.91
  • Revenue Per Share $0.15
  • Gross Profit 6.85 million
  • Quarterly Earnings Growth 1.6%
View More

Highlights

  • Market Capitalization 1.26 billion
  • EBITDA -78815000
  • Analyst Target Price $13.7
  • Book Value Per Share $4.42
View More

Share Statistics

  • Shares Outstanding 129.62 million
  • Shares Float 101.69 million
  • % Held by Insiders <1%
  • % Held by Institutions 2.87%
  • Shares Short 1.88 million
  • Shares Short Prior Month 2.82 million
  • Short Ratio 4.29
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.71
  • 52 Week High $21.28
  • 52 Week Low $3.12
  • 50 Day Moving Average 9.64
  • 200 Day Moving Average 12.23
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Mesoblast Limited (MESO) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Mesoblast Limited (MESO) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-26$N/A-$0.22-$0.15-43.61%
2020-09-302020-11-19$N/A-$0.21-$0.2619.04%
2020-06-302020-08-26$N/A-$0.30-$0.21-42.52%
2020-03-312020-05-27$12.08 million-$0.14-$0.1612.62%
2019-12-312020-02-26$2.21 million-$0.23-$0.13-71.64%
2019-09-302019-11-25$16.87 million-$0.06-$0.1970.27%
2019-06-302019-08-29$1.25 million-$0.21-$0.2724.04%
2019-03-312019-05-30$1.25 million-$0.25-$0.263.85%
2018-12-312019-02-20$1.87 million-$0.25-$0.23-8.7%
2018-09-302018-11-15$11.64 million-$0.20-$0.2311.52%
2018-06-302018-08-29$1.7 million-$0.22-$0.232.19%
2018-03-312018-05-30$1.07 million-$0.22-$0.22-1.59%
2017-12-312018-02-27$13.28 million$0.15-$0.20172.03%
2017-09-302017-11-14$1.11 million-$0.08-$0.2467.21%
2017-06-302017-08-29$473000-$0.32-$0.21-50.59%
2017-03-312017-05-24$820000-$0.12-$0.1935.26%
2016-12-312017-02-26$433000-$0.26-$0.20-34.92%
2016-09-302016-11-14$218000-$0.05-$0.2175.05%
2016-06-302016-08-24$26.62 million$0.64-$0.20423.54%
2016-03-312016-05-09$3.85 million-$0.04-$0.1263.7%
2015-12-312016-02-16$3.75 million-$0.31-$0.17-80.75%
2015-09-302015-12-16$7.25 million-$0.19

Mesoblast Limited (MESO) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Mesoblast Limited (MESO) Chart:

MESO chart by TradingView

Mesoblast Limited (MESO) News:

Below you will find a list of latest news for Mesoblast Limited (MESO) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Mesoblast Limited (MESO) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-04-1730CALL0 00TRUE00
2026-04-1740CALL0 00TRUE00
2026-04-1750CALL0 00TRUE00
2026-04-1760CALL0 00TRUE00
2026-04-1770CALL0 00TRUE00
2026-04-17810.3CALL0 00TRUE00
2026-04-1799.75CALL0 40TRUE00
2026-04-17104.7CALL5 1040TRUE4.70
2026-04-17110CALL0 00TRUE00
2026-04-17122.45CALL10 2410TRUE2.450
2026-04-17135.1CALL0 19269.35TRUE00
2026-04-17142.31CALL1 821324.88TRUE2.310
2026-04-17150.3CALL210 103169.55FALSE-0.35-0.54
2026-04-17160.4CALL0 762289.98FALSE00
2026-04-17170.15CALL0 655402.53FALSE00
2026-04-17180.52CALL0 733336.53FALSE00
2026-04-17190.15CALL3 771188.44FALSE0.150
2026-04-17200.05CALL0 1291663.9FALSE00
2026-04-17210.2CALL0 2961204.65FALSE00
2026-04-17220CALL0 0728.62FALSE00
2026-04-17230CALL0 0757.44FALSE00
2026-04-17240CALL0 0784.32FALSE00
2026-04-17250.05CALL0 4392278.31FALSE00
2026-04-17260CALL0 0833.2FALSE00
2026-04-17270CALL0 0855.56FALSE00
2026-04-17280CALL0 0876.73FALSE00
2026-04-17290CALL0 0896.82FALSE00
2026-04-17300.24CALL0 462915.93FALSE00
2026-04-17350.2CALL0 1058999.57FALSE00
2026-04-1730PUT0 00FALSE00
2026-04-1740PUT0 00FALSE00
2026-04-1750PUT0 00FALSE00
2026-04-1760PUT0 00FALSE00
2026-04-1770PUT0 01384.9FALSE00
2026-04-1780PUT0 01199.73FALSE00
2026-04-1790PUT0 01044.24FALSE00
2026-04-17101.7PUT0 0909.31FALSE00
2026-04-17111.85PUT0 13647.36FALSE00
2026-04-17120.2PUT0 16328.47FALSE00
2026-04-17130.15PUT1 70120.08FALSE0.150
2026-04-17140.3PUT1 25597.92FALSE0.30
2026-04-17151.48PUT100 14599.46TRUE-0.26-0.15
2026-04-17162.33PUT0 69303.24TRUE00
2026-04-17173.33PUT0 53153.99TRUE00
2026-04-17183.7PUT0 74161.61TRUE00
2026-04-17194.65PUT0 200TRUE00
2026-04-17205.6PUT0 210TRUE00
2026-04-17210PUT0 0193.16TRUE00
2026-04-17220PUT0 00TRUE00
2026-04-17230PUT0 00TRUE00
2026-04-17240PUT0 0248.48TRUE00
2026-04-17257.6PUT0 2264.84TRUE00
2026-04-17260PUT0 00TRUE00
2026-04-17270PUT0 00TRUE00
2026-04-17280PUT0 00TRUE00
2026-04-17290PUT0 0322.65TRUE00
2026-04-173010.2PUT0 3335.54TRUE00
2026-04-17350PUT0 00TRUE00
2026-05-1580CALL0 00TRUE00
2026-05-1590CALL0 00TRUE00
2026-05-15100CALL0 00TRUE00
2026-05-15110CALL0 087.99TRUE00
2026-05-15120CALL0 087.27TRUE00
2026-05-15130CALL0 0103.89TRUE00
2026-05-15141.75CALL0 30143.46TRUE00
2026-05-15152.32CALL1 0140.56FALSE2.320
2026-05-15162.02CALL1 178.24FALSE2.020
2026-05-15170.56CALL0 18190.56FALSE00
2026-05-15180.75CALL0 6385.28FALSE00
2026-05-15190CALL0 0220.99FALSE00
2026-05-15200CALL0 0234.02FALSE00
2026-05-15210CALL0 0245.95FALSE00
2026-05-15250CALL0 0285.6FALSE00
2026-05-1580PUT0 0425.35FALSE00
2026-05-1590PUT0 0370.33FALSE00
2026-05-15100PUT0 0322.6FALSE00
2026-05-15110PUT0 0280.08FALSE00
2026-05-15120PUT0 0155.96FALSE00
2026-05-15130.55PUT0 2364.3FALSE00
2026-05-15141.25PUT21 794.41FALSE0.40.47
2026-05-15152.49PUT0 625139.06TRUE00
2026-05-15162.6PUT0 1108.67TRUE00
2026-05-15170PUT0 096.9TRUE00
2026-05-15180PUT0 092.15TRUE00
2026-05-15190PUT0 089.47TRUE00
2026-05-15200PUT0 0100.21TRUE00
2026-05-15210PUT0 0105.46TRUE00
2026-05-15250PUT0 0137.88TRUE00
2026-07-1730CALL0 00TRUE00
2026-07-1740CALL0 00TRUE00
2026-07-1750CALL0 00TRUE00
2026-07-1760CALL0 00TRUE00
2026-07-1770CALL0 00TRUE00
2026-07-1780CALL0 086.75TRUE00
2026-07-1790CALL0 086.07TRUE00
2026-07-17106.25CALL0 2578.24TRUE00
2026-07-17110CALL0 087.95TRUE00
2026-07-17124.3CALL0 2180.59TRUE00
2026-07-17136.9CALL0 381.68TRUE00
2026-07-17146.3CALL0 481.79TRUE00
2026-07-17152.1CALL16 1072.81FALSE2.10
2026-07-17162.8CALL0 103102.22FALSE00
2026-07-17173.2CALL0 543109.52FALSE00
2026-07-17181.25CALL419 108976.55FALSE1.250
2026-07-17191.8CALL0 21130.64FALSE00
2026-07-17200.85CALL1 7176.78FALSE0.850
2026-07-17210.85CALL0 268141.85FALSE00
2026-07-17222.75CALL0 102148.26FALSE00
2026-07-17231.25CALL0 49154.21FALSE00
2026-07-17243CALL0 1159.76FALSE00
2026-07-17250.25CALL11 172372.48FALSE0.250
2026-07-17300CALL0 0186.89FALSE00
2026-07-17350CALL0 0204.11FALSE00
2026-07-1730PUT0 0691.77FALSE00
2026-07-1740PUT0 0493.14FALSE00
2026-07-1750PUT0 0397.51FALSE00
2026-07-1760PUT0 0334.07FALSE00
2026-07-1770PUT0 0286.53FALSE00
2026-07-1780PUT0 0248.4FALSE00
2026-07-1790PUT0 0216.42FALSE00
2026-07-17100PUT0 0188.68FALSE00
2026-07-17111.15PUT0 8163.99FALSE00
2026-07-17120PUT0 0141.48FALSE00
2026-07-17130PUT0 0122.42FALSE00
2026-07-17142.48PUT100 5154.32FALSE2.480
2026-07-17152.65PUT0 17685.73TRUE00
2026-07-17163.6PUT0 8291.69TRUE00
2026-07-17173.4PUT0 2192.54TRUE00
2026-07-17184.95PUT0 3588.5TRUE00
2026-07-17195.25PUT0 1193.42TRUE00
2026-07-17206.5PUT0 1093.8TRUE00
2026-07-17210PUT0 091.18TRUE00
2026-07-17220PUT0 093.33TRUE00
2026-07-17230PUT0 096.91TRUE00
2026-07-17240PUT0 093.25TRUE00
2026-07-17250PUT0 090.58TRUE00
2026-07-17300PUT0 0101.22TRUE00
2026-07-17350PUT0 0108.86TRUE00
2026-10-1630CALL0 00TRUE00
2026-10-1650CALL0 00TRUE00
2026-10-1690CALL0 081.64TRUE00
2026-10-16100CALL0 076.73TRUE00
2026-10-16110CALL0 079.58TRUE00
2026-10-16120CALL0 081.42TRUE00
2026-10-16130CALL0 081.39TRUE00
2026-10-16140CALL0 081.32TRUE00
2026-10-16150CALL0 080.08FALSE00
2026-10-16160CALL0 080.28FALSE00
2026-10-16174.3CALL0 3080.72FALSE00
2026-10-16180CALL0 087.49FALSE00
2026-10-16190CALL0 092.35FALSE00
2026-10-16200CALL0 096.63FALSE00
2026-10-16210CALL0 0101.64FALSE00
2026-10-16220CALL0 0105.05FALSE00
2026-10-16250CALL0 0118.26FALSE00
2026-10-16300CALL0 0132.79FALSE00
2026-10-1630PUT0 0499.68FALSE00
2026-10-1650PUT0 0286.21FALSE00
2026-10-1690PUT0 0156.2FALSE00
2026-10-16100PUT0 0136.35FALSE00
2026-10-16110PUT0 0120.31FALSE00
2026-10-16120PUT0 0104.08FALSE00
2026-10-16130PUT0 094.52FALSE00
2026-10-16143.2PUT0 50090.16FALSE00
2026-10-16150PUT0 086.39TRUE00
2026-10-16160PUT0 090.39TRUE00
2026-10-16170PUT0 088.57TRUE00
2026-10-16180PUT0 085.99TRUE00
2026-10-16190PUT0 088.71TRUE00
2026-10-16200PUT0 085.95TRUE00
2026-10-16210PUT0 088.71TRUE00
2026-10-16220PUT0 088.51TRUE00
2026-10-16250PUT0 091.71TRUE00
2026-10-16300PUT0 092.9TRUE00
2027-01-1530CALL0 081TRUE00
2027-01-15510.44CALL0 10TRUE00
2027-01-1588.5CALL0 285.27TRUE00
2027-01-15106.9CALL0 26672.16TRUE00
2027-01-15125.5CALL4 1085.03TRUE5.50
2027-01-15130CALL0 00TRUE00
2027-01-15154.5CALL0 4084.22FALSE00
2027-01-15174.45CALL0 46679.03FALSE00
2027-01-15203.2CALL0 38785.24FALSE00
2027-01-15223.1CALL0 9391.24FALSE00
2027-01-15251.7CALL0 7395.22FALSE00
2027-01-15271.35CALL0 414100.83FALSE00
2027-01-15302CALL0 54108.18FALSE00
2027-01-15351CALL0 3119.37FALSE00
2027-01-1530PUT0 0413.75FALSE00
2027-01-1550.55PUT0 1236.24FALSE00
2027-01-1580PUT0 0148.07FALSE00
2027-01-15103.6PUT0 2114.41FALSE00
2027-01-15120PUT0 092.64FALSE00
2027-01-15130PUT0 00FALSE00
2027-01-15155.04PUT0 1188.86TRUE00
2027-01-15170PUT0 086.15TRUE00
2027-01-15207.93PUT0 390.24TRUE00
2027-01-15220PUT0 090.93TRUE00
2027-01-15250PUT0 092.64TRUE00
2027-01-15270PUT0 091.49TRUE00
2027-01-15300PUT0 097.43TRUE00
2027-01-15350PUT0 0100.63TRUE00
2028-01-21311.6CALL15 3390TRUE11.60
2028-01-2159.8CALL74 2640TRUE-0.5-0.05
2028-01-2187.85CALL119 10452.83TRUE-0.35-0.04
2028-01-21106.97CALL60 23360.54TRUE-0.23-0.03
2028-01-21126.25CALL3 18864.68TRUE6.250
2028-01-21155.3CALL16 17367.2FALSE5.30
2028-01-21174.7CALL687 152367.18FALSE-0.3-0.06
2028-01-21204.26CALL339 219971.15FALSE-0.27-0.06
2028-01-21224.01CALL180 105673.18FALSE-0.1-0.02
2028-01-21253.4CALL453 92771.99FALSE-0.3-0.08
2028-01-21273.02CALL60 50470.9FALSE-0.28-0.08
2028-01-21302.75CALL760 41472.33FALSE-0.15-0.05
2028-01-21352.32CALL345 72473.38FALSE-0.09-0.04
2028-01-2130PUT0 0282.01FALSE00
2028-01-2150PUT0 0158.93FALSE00
2028-01-2181.71PUT0 1275.3FALSE00
2028-01-21102.87PUT1 7484.3FALSE2.870
2028-01-21124.02PUT0 6064.54FALSE00
2028-01-21154.75PUT0 2985.25TRUE00
2028-01-21170PUT0 086.79TRUE00
2028-01-21209PUT0 1083.77TRUE00
2028-01-212211PUT0 1083.17TRUE00
2028-01-212512.5PUT0 3084.47TRUE00
2028-01-21270PUT0 089.06TRUE00
2028-01-21300PUT0 088.51TRUE00
2028-01-21350PUT0 083.62TRUE00
2030-12-18100.2CALL456 3400TRUE-3.3-0.94
2030-12-18250PUT 0TRUE00

Latest MESO Trades:

Date Shares Price
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:54 PM EST100$2.645
Jun 13, 2022 7:55 PM EST100$2.64
Jun 13, 2022 7:57 PM EST186$2.66
Jun 13, 2022 7:57 PM EST14$2.66

Mesoblast Limited (MESO) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-01-30SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000119312520019148/0001193125-20-019148-index.htm
2020-07-27S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1345099/000121390020018628/0001213900-20-018628-index.htm
2020-05-26DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1345099/000134509920000001/0001345099-20-000001-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1345099/000142284920000077/0001422849-20-000077-index.htm
2019-09-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034209/0001564590-19-034209-index.htm
2019-09-0920-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034304/0001564590-19-034304-index.htm
2019-09-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019034483/0001564590-19-034483-index.htm
2019-10-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036315/0001564590-19-036315-index.htm
2019-10-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036431/0001564590-19-036431-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019036737/0001564590-19-036737-index.htm
2019-10-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019037256/0001564590-19-037256-index.htm
2019-11-016-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019039260/0001564590-19-039260-index.htm
2019-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019041204/0001564590-19-041204-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044600/0001564590-19-044600-index.htm
2019-11-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044601/0001564590-19-044601-index.htm
2019-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019044825/0001564590-19-044825-index.htm
2019-12-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019045775/0001564590-19-045775-index.htm
2019-12-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459019046754/0001564590-19-046754-index.htm
2020-01-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020000984/0001564590-20-000984-index.htm
2020-01-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020001658/0001564590-20-001658-index.htm
2020-02-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003090/0001564590-20-003090-index.htm
2020-02-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020003512/0001564590-20-003512-index.htm
2020-02-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020004688/0001564590-20-004688-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020006501/0001564590-20-006501-index.htm
2020-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020007597/0001564590-20-007597-index.htm
2020-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020009861/0001564590-20-009861-index.htm
2020-03-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020011865/0001564590-20-011865-index.htm
2020-03-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020012613/0001564590-20-012613-index.htm
2020-04-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020014830/0001564590-20-014830-index.htm
2020-04-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020015584/0001564590-20-015584-index.htm
2020-04-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020016005/0001564590-20-016005-index.htm
2020-04-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020017344/0001564590-20-017344-index.htm
2020-04-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020018322/0001564590-20-018322-index.htm
2020-05-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020020611/0001564590-20-020611-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020022226/0001564590-20-022226-index.htm
2020-05-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020025586/0001564590-20-025586-index.htm
2020-05-196-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026055/0001564590-20-026055-index.htm
2020-05-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020026914/0001564590-20-026914-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027408/0001564590-20-027408-index.htm
2020-05-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020027410/0001564590-20-027410-index.htm
2020-06-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020028116/0001564590-20-028116-index.htm
2020-06-186-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020029698/0001564590-20-029698-index.htm
2020-06-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020030668/0001564590-20-030668-index.htm
2020-07-026-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031530/0001564590-20-031530-index.htm
2020-07-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020031863/0001564590-20-031863-index.htm
2020-07-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020032147/0001564590-20-032147-index.htm
2020-07-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020033456/0001564590-20-033456-index.htm
2020-08-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020035263/0001564590-20-035263-index.htm
2020-08-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020038657/0001564590-20-038657-index.htm
2020-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020039445/0001564590-20-039445-index.htm
2020-08-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020040358/0001564590-20-040358-index.htm
2020-08-256-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041082/0001564590-20-041082-index.htm
2020-08-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020041869/0001564590-20-041869-index.htm
2020-09-0320-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042401/0001564590-20-042401-index.htm
2020-09-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042407/0001564590-20-042407-index.htm
2020-09-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020042713/0001564590-20-042713-index.htm
2020-09-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043641/0001564590-20-043641-index.htm
2020-09-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020043751/0001564590-20-043751-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020045777/0001564590-20-045777-index.htm
2020-10-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020046432/0001564590-20-046432-index.htm
2020-10-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020047335/0001564590-20-047335-index.htm
2020-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020048488/0001564590-20-048488-index.htm
2020-11-036-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1345099/000156459020049709/0001564590-20-049709-index.htm